1614669
USP
Natriumstärkeglycolat Typ A
United States Pharmacopeia (USP) Reference Standard
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
Empfohlene Produkte
Qualität
pharmaceutical primary standard
API-Familie
starch
Hersteller/Markenname
USP
Anwendung(en)
pharmaceutical (small molecule)
Format
neat
Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich
Allgemeine Beschreibung
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Anwendung
Sodium Starch Glycolate Type A USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Sodium Starch Glycolate
Hinweis zur Analyse
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Sonstige Hinweise
Sales restrictions may apply.
Ähnliches Produkt
Produkt-Nr.
Beschreibung
Preisangaben
Lagerklassenschlüssel
11 - Combustible Solids
WGK
WGK 1
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Kunden haben sich ebenfalls angesehen
Ritesh M Pabari et al.
International journal of pharmaceutics, 430(1-2), 18-25 (2012-04-03)
A two factor, three level (3(2)) face centred, central composite design (CCD) was applied to investigate the main and interaction effects of tablet diameter and compression force (CF) on hardness, disintegration time (DT) and porosity of mannitol based orodispersible tablets
Alvaro Goyanes et al.
Drug development and industrial pharmacy, 37(7), 825-831 (2011-03-17)
Chitosan-silica coprecipitate (C-S) has recently been proposed as a tablet disintegrant. In this study we compared it with a 1:1 physical mixture of chitosan and silica (C/S) at the same composition as the coprecipitate, and with the widely used commercial
M Maghsoodi et al.
Pharmaceutical development and technology, 16(3), 243-249 (2010-02-24)
Spherical crystallization (SC) of carbamazepine (CBZ) was carried out for preparation of the agglomerates using the solvent change method. The potential of the intraagglomerate addition of sodium starch glycolate (SSG) as a disintegrant agent and povidone (PVP) as a hydrophilic
John Rojas et al.
AAPS PharmSciTech, 13(4), 1054-1062 (2012-08-18)
Spironolactone is a drug derived from sterols that exhibits an incomplete oral absorption due to its low water solubility and slow dissolution rate. In this study, formulations of spironolactone with four disintegrants named as croscarmellose sodium, crospovidone, sodium starch glycolate
Samata Mehta et al.
International journal of pharmaceutics, 422(1-2), 310-317 (2011-11-22)
A design of experiments (DOE) approach (2-level full factorial design) was used to investigate the effect of several formulation and process variables on the properties of fast disintegrating tablets comprising starch-based pellets and excipient granules and to optimize and validate
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.